Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58

by Bhatt, D.L, Gause-Nilsson, I., Kolkailah, A.A, Leiter, L.A, McGuire, D.K, Mosenzon, O., Murphy, S.A, Raz, I., Sabatine, M.S, Wilding, J.P.H, Wiviott, S.D
Published 2022

Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides

by Bhatt, D.L, Mason, R.P, Pareek, M.
Published 2022

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

by Anderson, J.E, Bakris, G.L, Ballantyne, C.M, Beckman, J.A, Bhatt, D.L, Bloomgarden, Z.T, Bozkurt, B., Budoff, M.J, Butler, J., Dagogo-Jack, S., de Boer, I.H, DeFronzo, R.A, Eckel, R.H, Einhorn, D., Fonseca, V.A, Green, J.B, Grunberger, G., Guerin, C., Handelsman, Y., Inzucchi, S.E, Jellinger, P.S, Kosiborod, M.N, Kushner, P., Lepor, N., Mende, C.W, Michos, E.D, Plutzky, J., Taub, P.R, Umpierrez, G.E, Vaduganathan, M., Weir, M.R
Published 2022

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial

by Aboyans, V., Alings, M., Anand, S.S, Avezum, A., Bhatt, D.L, Bosch, J., Branch, K.R.H, Bruns, N.C, Chen, E., Commerford, P.J, Connolly, S.J, Dagenais, G.R, Dans, A.L, Diaz, R., Eikelboom, J.W, Ertl, G., Felix, C., Fox, K.A.A, Guzik, T.J, Ha, J.-W, Hart, R.G, Hori, M., Kakkar, A., Keltai, K., Keltai, M., Kim, J.-H, Lamy, A., Lanas, F., Lanius, V., Leong, D.P, Lewis, B.S, Liang, Y., Liu, L., Lonn, E.M, Lopez-Jaramillo, P., Maggioni, A.P, Metsarinne, K.P, Misselwitz, F., Moayyedi, P., O'Donnell, M., Parkhomenko, A.N, Piegas, L.S, Pogosova, N., Probstfield, J.L, Ryden, L., Sharma, M., Steg, P.G, Störk, S., Tonkin, A.M, Torp-Pedersen, C., Varigos, J.D, Verhamme, P.B, Vinereanu, D., Widimsky, P., Yuan, F., Yusoff, K., Yusuf, S., Zhu, J.
Published 2017

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

by Alings, M., Anand, S.S, Avezum, A., Bhatt, D.L, Bosch, J., Branch, K.R.H, Bruns, N.C, Commerford, P.J, COMPASS Investigators, Connolly, S.J, Dagenais, G.R, Dans, A.L, Diaz, R., Dyal, L., Eikelboom, J.W, Ertl, G., Felix, C., Fox, K.A.A, Guzik, T.J, Hart, R.G, Hori, M., Kakkar, A.K, Keltai, M., Kim, J.-H, Lanas, F., Leong, D., Lewis, B.S, Liang, Y., Lonn, E.M, Lopez-Jaramillo, P., Maggioni, A.P, Metsarinne, K.P, Moayyedi, P., Muehlhofer, E., O'Donnell, M., Parkhomenko, A.N, Piegas, L.S, Pogosova, N., Probstfield, J., Ryden, L., Shestakovska, O., Steg, P.G, Störk, S., Tonkin, A.M, Torp-Pedersen, C., Verhamme, P.B, Vinereanu, D., Widimsky, P., Yusoff, K., Yusuf, S., Zhu, J.
Published 2019

Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial

by Alings, M., Anand, S.S, Avezum, A., Bhatt, D.L, Bosch, J., Branch, K.R.H, Commerford, P.J, COMPASS Investigators, Connolly, S.J, Cook Bruns, N., Dagenais, G.R, Dans, A., Diaz, R., Dyal, L., Eikelboom, J.W, Ertl, G., Felix, C., Fox, K.A.A, Guzik, T., Hart, R.G, Hori, M., Kakkar, A., Keltai, M., Kim, J.-H, Lanas, F., Leong, D., Lewis, B.S, Liang, Y., Lonn, E.M, Lopez-Jaramillo, P., Maggioni, A.P, Metsarinne, K., Moayyedi, P., Muehlhofer, E., O'Donnell, M., Parkhomenko, A.N, Piegas, L.S, Pogosova, N., Probstfield, J., Ryden, L., Shestakovska, O., Steg, P.G, Störk, S., Tonkin, A.M, Torp-Pedersen, C., Verhamme, P.B, Vinereanu, D., Widimsky, P., Yusoff, K., Yusuf, S., Zhu, J.
Published 2019